2017 ASCO RECAP: The Latest in Colorectal Cancer Research #CRCWebinar

transcript

2017 ASCO RECAP: The Latest in

Colorectal Cancer Research

Our webinar will begin shortly.

WELCOME!

• Speaker: Dustin Deming, MD

• Archived Webinars: FightCRC.org/webinars

• AFTER THE WEBINAR: Expect an email with links to the

material & a survey. If you fill it out, we’ll send you an “I

booty” bracelet

• Ask a question in the panel on the RIGHT SIDE of your

screen

• Follow along via Twitter – use the hashtag #CRCWebinar

Today’s Webinar:

Resources:

Disclaimer

The information and services provided by Fight Colorectal

Cancer are for general informational purposes only. The

information and services are not intended to be substitutes

for professional medical advice, diagnoses or treatment.

If you are ill, or suspect that you are ill, see a doctor

immediately. In an emergency, call 911 or go to the nearest

emergency room.

Fight Colorectal Cancer never recommends or endorses any

specific physicians, products or treatments for any condition.

Speaker:

Dustin Deming, MD, is a gastrointestinal

oncologist and colorectal cancer laboratory

researcher at the University of Wisconsin Carbone

Cancer Center.

He has a subspecialty focus in the treatment of

colon, rectal and anal cancers. At the age of 31, he

was diagnosed with stage III rectal cancer, the very

disease he has dedicated to treating and advancing

therapies for.

As both a practitioner, researcher AND a patient, he

knows first-hand what the cancer journey is like; he

aims his research to fundamentally change the way

in which we treat gastrointestinal cancers to amore

personalized approach.

ASCO Update 2017:Colorectal Cancer

Dustin Deming, MD

McArdle Laboratory for Cancer Research

Carbone Cancer Center

University of Wisconsin

6/23/2017

Outline

• Metastatic Cancer: Advances in Immunotherapy

• Metastatic Cancer: Advances in Precision Medicine

• Adjuvant Chemotherapy: 3 vs 6 months

• Survivorship Care

Metastatic Cancer: Advances in Immunotherapy

• Nivolumab and Ipilimumab for MSI-H CRC

• CEA-TCB Bispecific Antibody

• Versican Proteolysis as a New Immune Biomarker

Combination of nivolumab (nivo) + ipilimumab (ipi) in the treatment of patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC): CheckMate 142 study.

Presented by: Thierry Andre, MD

Nivolumab and Ipilimumab for MMR deficient cancers

CEA-TCB Antibody

Safety profile of CEA-TCB was manageable as monotherapy and <br />in combination with atezolizumab

Presented By Josep Tabernero at 2017 ASCO Annual Meeting

CEA-TCB at doses of ≥ 60 mga demonstrated clinical activity in mCRC as monotherapy and in combination with atezolizumab

CEA-TCB at doses ≥ 60 mg + atezolizumab demonstrated enhanced clinical activity vs monotherapy in mCRC

CEA-TCB at doses ≥ 60 mg + atezolizumab demonstrated promising clinical activity in 3L+ patients with MSS mCRC

Versican Proteolysis

• A new biomarker for immune infiltration in colorectal cancers

Interaction Between Cancer Genomics and the Tumor Microenvironment

Dr. Fotis Asimakopoulos

VCAN Proteolysis Correlates with CD8+ T-Cell Infiltration

Metastatic Cancer: Advances in Precision Medicine• Cetuximab, Vemurafenib and Irinotecan for BRAF

mutant cancers

Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406)

Presented By Scott Kopetz at 2017 ASCO Annual Meeting

Introduction

Study Design

Grade 3/4 Adverse Events

Primary Endpoint: Progression-free survival

Response Rate

Subgroup Analyses

Secondary Endpoint: Overall Survival

Adjuvant Chemotherapy for Stage III Colon Cancer:

3 vs 6 months duration

Prospective Pooled Analysis of Six Phase III Trials Investigating Duration of Adjuvant Oxaliplatin-based therapy (3 vs. 6 months) for Patients with Stage III Colon Cancer: <br />The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration

Presented By Qian Shi at 2017 ASCO Annual Meeting

Study Schema

IDEA Trials Summary

Adverse Events

Primary DFS Analysis (mITT)

Primary DFS Analysis (mITT), cont.

DFS Comparison by Risk Group and Regimen, cont.

Recommendations Going Forward

Ways Oncologists are Thinking About this Data

• 6 months of adjuvant chemotherapy for everyone

• 3 months for low risk and 6 months for high risk

• Give oxaliplatin for first 3 months only, and finish with infusional 5FU for total of 6 months

• Maybe CAPEOX is better than FOLFOX

Dusty’s Opinion

• Risk/benefit ratio approach

Survivorship Care

• Tree Nuts

• Vitamin D

• PET/CT scans

Nut Consumption and Survival in Stage III Colon Cancer Patients: Results from CALGB 89803 (Alliance)

CALGB 89803

Results

Some preclinical rationale

Analysis of serum vitamin D levels and prognosis in stage III colon carcinoma patients treated with adjuvant FOLFOX+/- cetuximab chemotherapy: NCCTG N0147 (Alliance)

Vitamin D by Tertile with Outcome

Secondary analyses of 89803

What do I do or at least try to do?

• Aspirin – 81-325mg per day

• Exercise – Half hour of moderate exercise more days than not

• Multi-vitamin

• Low glycemic index diet

• Coffee

• Tree nuts or tree nut products

Question & Answer:

SNAP A #STRONGARMSELFIEBayer HealthCare will donate $1 for every photo posted (up to $25,000).

Flex a “strong arm” & post it to Twitter or Instagram! (Use the hashtag!)

Contact Us!

2017 ASCO RECAP: The Latest in Colorectal Cancer Research #CRCWebinar

Health & Medicine